What is SparingVision?
SparingVision operates at the intersection of advanced biotechnology and clinical ophthalmology. As a genomic medicines company, the firm is dedicated to addressing the root causes of retinal degeneration, a field characterized by high unmet medical needs. By leveraging cutting-edge gene therapy platforms, SparingVision aims to move beyond symptomatic management to provide curative or disease-modifying treatments. Its market position is bolstered by a robust intellectual property portfolio and a strategic focus on high-impact therapeutic areas, making it a critical player in the next generation of ocular healthcare innovation.
How much funding has SparingVision raised?
SparingVision has raised a total of $130.5M across 3 funding rounds:
Grant
$2.8M
Series A
$52.7M
Series B
$75M
Grant (2019): $2.8M with participation from European EIC Accelerator
Series A (2020): $52.7M led by Foundation Fighting Blindness, University of Pittsburgh Medical Centre Enterprise, Jeito Capital, Bpifrance, 4BIO Capital, and Ysios Capital
Series B (2022): $75M supported by Jeito, University of Pittsburgh Medical Center Enterprise, Bpifrance, 4BIO Capital, Retinal Degeneration Fund, and Ysios Capital
Key Investors in SparingVision
Jeito Capital
Jeito Capital is a global investment firm that finances and accelerates the growth of ground-breaking medical innovations, focusing on building market leaders in therapeutic areas with high patient impact.
Bpifrance
Bpifrance is a French public investment bank that supports companies at every stage of development through credit, guarantees, and equity, with a strong emphasis on innovation and international expansion.
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to develop novel therapies for unmet medical needs.
What's next for SparingVision?
With the recent infusion of $75M, SparingVision is poised to transition its lead candidates through critical clinical development phases. The strategic roadmap likely involves expanding manufacturing capabilities and strengthening international regulatory engagement to ensure rapid market access. As the company scales, the focus will remain on executing rigorous clinical trials and fostering partnerships that enhance its therapeutic reach. The continued support from specialized life sciences investors suggests a long-term commitment to building a market-leading entity capable of delivering transformative outcomes for patients globally.
See full SparingVision company page
